We therefore investigated the in vivo activity of tucatinib, T-DM1, and the combination of the two against three HER2-amplified breast cancer xenograft models derived from patients (PDX) that had shown clinical disease progression with trastuzumab combination regimens and were refractory to T-DM1 monotherapy in vivo. The gene discussed is ERBB2; the disease is breast cancer.